9-(((E)-4-((2S,3R,4R,5S)-3,4-二羟基-5-(((2S,3S)-3-((2S,3S)-3-羟基丁烷-2-基)环氧乙烷-2-基)甲基)四氢-2H-吡喃-2-基)-3-甲基丁-2-烯酰基)氧基)壬酸锂酯

Mupirocin lithium

产品编号.: A346799 CAS号: 73346-79-9
分子式: C26H43LiO9 分子量: 506.5552
纯度: 95% MDL NO.:

中文名称:9-(((E)-4-((2S,3R,4R,5S)-3,4-二羟基-5-(((2S,3S)-3-((2S,3S)-3-羟基丁烷-2-基)环氧乙烷-2-基)甲基)四氢-2H-吡喃-2-基)-3-甲基丁-2-烯酰基)氧基)壬酸锂酯 
CAS号:73346-79-9
中文别名:莫匹罗星锂;假单胞菌酸锂;莫匹罗星锂 EP标准品;莫匹罗星锂 USP标准品;9-(((E)-4-((2S,3R,4R,5S)-3,4-二羟基-5-(((2S,3S)-3-((2S,3S)-3-羟基丁烷-2-基)环氧乙烷-2-基)甲基)四氢-2H-吡喃-2-基)-3-甲基丁-2-烯酰基)氧基)壬酸锂酯
英文名称:Mupirocin lithium
英文别名:Mupirocin Lithium;Lithium mupirocin, Lithium pseudomonate;lithium,9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate;9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid lithium salt;Li-MUP;Lithium mupirocin;Lithium mupirocin solution;Lithium mupirocin Supplement;Pseudomonic acid A lithium salt;AK239162;lithium;9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate;Mupirocin lithium, United States Pharmacopeia (USP) Reference Standard;Lithium9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoate;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate (non-preferred name);Mupirocin (lithium);CS-0162433;73346-79-9;AKOS027276158;HY-W108875;BS-17476;DTXSID50746663;BRL-4910A;Pseudomonic acid;Lithium mupirocin Supplement, for microbiology;D70855;Lithium 9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoate;Mupirocin lithium, European Pharmacopoeia (EP) Reference Standard;mupirocin lithium;Mupirocin lithium, British Pharmacopoeia (BP) Reference Standard;LITHIUM(1+) 9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-DIHYDROXY-5-{[(2S,3S)-3-[(2S,3S)-3-HYDROXYBUTAN-2-YL]OXIRAN-2-YL]METHYL}OXAN-2-YL]-3-METHYLBUT-2-ENOYL]OXY}NONANOATE;SCHEMBL1537257;Lithium mupirocin, >=95.0% (HPLC);YCA34679;MUPIROCIN LITHIUM (100 MG)H0C176926UG/MG(AI);MUPIROCIN LITHIUM (100 MG)H0C176926UG/MG(AI);MUPIROCIN LITHIUM (100 MG)H0C176926UG/MG(AI);XFIKMPRBSORKQP-JATHGWPISA-M;XFIKMPRBSORKQP-JATHGWPISA-M;XFIKMPRBSORKQP-JATHGWPISA-M;Mupirocin Lithium; BRL-4910B; Bactroban related;Mupirocin Lithium; BRL-4910B; Bactroban related;Mupirocin Lithium; BRL-4910B; Bactroban related;DA-75039;DA-75039;DA-75039;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate
EINEC:
分子式:C26H43LIO9
分子量:506.5552
搜索质检报告(COA)
搜索MSDS
已经到最底了
批量搜索 关闭
批处理可以通过CAS号,CAS号,每行一个搜索
...

9-(((E)-4-((2S,3R,4R,5S)-3,4-二羟基-5-(((2S,3S)-3-((2S,3S)-3-羟基丁烷-2-基)环氧乙烷-2-基)甲基)四氢-2H-吡喃-2-基)-3-甲基丁-2-烯酰基)氧基)壬酸锂酯
Mupirocin Lithium;Lithium mupirocin, Lithium pseudomonate;lithium,9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate;9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid lithium salt;Li-MUP;Lithium mupirocin;Lithium mupirocin solution;Lithium mupirocin Supplement;Pseudomonic acid A lithium salt;AK239162;lithium;9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate;Mupirocin lithium, United States Pharmacopeia (USP) Reference Standard;Lithium9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoate;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate (non-preferred name);Mupirocin (lithium);CS-0162433;73346-79-9;AKOS027276158;HY-W108875;BS-17476;DTXSID50746663;BRL-4910A;Pseudomonic acid;Lithium mupirocin Supplement, for microbiology;D70855;Lithium 9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoate;Mupirocin lithium, European Pharmacopoeia (EP) Reference Standard;mupirocin lithium;Mupirocin lithium, British Pharmacopoeia (BP) Reference Standard;LITHIUM(1+) 9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-DIHYDROXY-5-{[(2S,3S)-3-[(2S,3S)-3-HYDROXYBUTAN-2-YL]OXIRAN-2-YL]METHYL}OXAN-2-YL]-3-METHYLBUT-2-ENOYL]OXY}NONANOATE;SCHEMBL1537257;Lithium mupirocin, >=95.0% (HPLC);YCA34679;MUPIROCIN LITHIUM (100 MG)H0C176926UG/MG(AI);MUPIROCIN LITHIUM (100 MG)H0C176926UG/MG(AI);MUPIROCIN LITHIUM (100 MG)H0C176926UG/MG(AI);XFIKMPRBSORKQP-JATHGWPISA-M;XFIKMPRBSORKQP-JATHGWPISA-M;XFIKMPRBSORKQP-JATHGWPISA-M;Mupirocin Lithium; BRL-4910B; Bactroban related;Mupirocin Lithium; BRL-4910B; Bactroban related;Mupirocin Lithium; BRL-4910B; Bactroban related;DA-75039;DA-75039;DA-75039;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate;Lithium 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoyl}oxy)nonanoate